Publication date: Sep 06, 2025
A 46-year-old man was diagnosed with anti jo-1 antibody-positive dermatomyositis 11 years ago and had been treated with prednisolone and tacrolimus. In the present case, after contracting SARS CoV2 virus infection, his dyspnea rapidly worsened, and he presented with renal and cardiac failure. Based on the biopsy results of the same area and anti-U1-RNP antibody positivity, he was diagnosed with systemic sclerosis and scleroderma renal crisis and required hemodialysis. A renal biopsy performed later showed tubular atrophy, intratubular cell debris, and endothelial cell damage, consistent with scleroderma renal crisis. Although rapid skin hardening and high-dose glucocorticoid use are known risks for scleroderma renal crisis, scleroderma renal crisis triggered by novel SARS CoV-2 virus infection has never been reported before and is very rare. It is crucial to identify the relationship between the scleroderma renal crisis and SARS CoV-2 virus infection. This relationship can be explained through the RAS system, which is believed to play a role in the development of both.
| Concepts | Keywords |
|---|---|
| 11years | Renin angiotensin system |
| Cardiac | SARS-CoV-2virus |
| Dermatomyositis | Scleroderma renal crisis |
| Renal | Systemic sclerosis |
| Virus |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | dermatomyositis |
| disease | MESH | COVID-19 |
| disease | MESH | infection |
| drug | DRUGBANK | Prednisolone |
| drug | DRUGBANK | Tacrolimus |
| disease | MESH | virus infection |
| disease | MESH | dyspnea |
| disease | MESH | cardiac failure |
| disease | MESH | systemic sclerosis |
| disease | MESH | atrophy |
| disease | IDO | cell |
| drug | DRUGBANK | Rasagiline |
| disease | IDO | role |